NCT05572125 is a clinical trial in Erythropoietic Protoporphyria, sponsored by Bispebjerg Hospital.

Who is sponsoring NCT05572125?

NCT05572125 is sponsored by Bispebjerg Hospital.

What condition does NCT05572125 study?

NCT05572125 studies Erythropoietic Protoporphyria, Iron-deficiency.

Is NCT05572125 still recruiting?

NCT05572125 is currently completed. Last updated 23 February 2023.

Last reviewed 2023-02-23 · How we verify

NCT05572125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iron Therapy in Erythropoietic Protoporphyria

Completed Last updated 23 February 2023

What this trial tests

trial in Erythropoietic Protoporphyria in 10 participants. Completed in 14 February 2023.

Timeline

17 October 2022

Primary endpoint
14 February 2023

14 February 2023

Quick facts

Lead sponsor	Bispebjerg Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	17 October 2022
Primary completion	14 February 2023
Estimated completion	14 February 2023
Sites	1 location across Denmark

Conditions studied

Erythropoietic Protoporphyria — all drugs for Erythropoietic Protoporphyria →
Iron-deficiency — all drugs for Iron-deficiency →

Sponsor

Bispebjerg Hospital

Who can join

15 and older, any sex, with Erythropoietic Protoporphyria or Iron-deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Giving oral iron to patients with erythropoietic protoporphyria (EPP) who is iron deficient is thought to be beneficial. This is, however, not well documented. The purpose of this study is to investigate the effect and safety of oral iron in patients with EPP who is taking iron tablets due to iron deficiency.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bispebjerg Hospital trials

Trials by the same sponsor.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT07373587 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy · NA · not yet recruiting
NCT07123558 — Anal Cancer Prevention in High-Risk Categories of Men Who Have Sex With Men · NA · not yet recruiting
NCT07124338 — Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Feasibili · NA · active not recruiting
NCT07096648 — Alert Burden When Monitoring Patients at Home · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05572125 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bispebjerg Hospital
Last refreshed: 23 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05572125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing